The research domain criteria framework in drug discovery for neuropsychiatric diseases: focus on negative valence. (October 2018)

• Record Type: Journal Article
• Authors: Nicholson, Janet R.; Sommer, Bernd
• Is Part Of: Brain and neuroscience advances. Volume 2(2018)
• Publication Date: 2018-10
• Subjects: Drug discovery -- neuropsychiatry -- research domain criteria -- negative valence -- anxiety -- RDoC; Brain -- Periodicals; Neurosciences -- Periodicals; Brain; Nervous System; Brain; Neurosciences; Periodicals; Periodical; 616.8
• DOI: 10.1177/2398212818804030
• Languages: English
• ISSNs: 2398-2128

Abstract

Drug discovery, particularly in the field of central nervous system, has had very limited success in the last few decades. A likely contributor is the poor translation between preclinical and clinical phases. The Research Domain Criteria of the National Institutes of Mental Health is a framework which aims to identify new ways of classifying mental illnesses that are based on observable behaviour and neurobiological measures, and to provide a guiding and evolving framework to improve the translation from preclinical to clinical research. At the core of the Research Domain Criteria approach is the assumption that the dimensional constructs described can be assessed across different units of analysis, thus enabling a more precise quantitative understanding of their neurobiological underpinnings, increasing the likelihood of identifying new and effective therapeutic approaches. In the present review, we discuss how the Research Domain Criteria can be applied to drug discovery with the domain Negative Valence, construct Potential Threat ('Anxiety') as an example. We will discuss the evidence supporting the utility of the Research Domain Criteria approach and evaluate how close we are to achieving a common thread of translational research from gene to self-report.